Čeština
|
Dansk
|
Deutsch
|
English
|
Español
|
Français
|
Italiano
|
Nederlands
|
Norsk
|
Polski
|
Português
|
Pусский
|
Suomi
|
Svenska
|
US
EHDN2016
DOENÇA
GRUPO
REGISTRY
PROJECTS
ENTRAR
EHDN2012 - Documents - Presentations
-
Notícias
O projecto
Patrocínio
Comité Executivo
Writing Committee Strategic ...
Comité Revisão Científico
Coordenação Central
Coordenação Idioma
Fellowship Programme
Constitution
Voting/Nomination
Membros
Request
Centros
Grupos de trabalho
Eventos
EHDN 2016
EHDN 2014
EHDN 2012
Introduction
Announcement
Programme Fri
Programme Sat
Programme Sun
Additional Meetings
Important Dates
Registration
Travel & Accommodation
EHA Registration
EHA Programme
Reception Dinner
About Stockholm
Abstract Submission
Reimbursement
Documents
Handouts
Presentations
Posters
Contacts
Feedback & Evaluation
EHDN 2010
EHDN 2008
EHDN 2007
EHDN 2006
EHDN 2005
Final Programme
Plenary Dinner
Registration
Working Groups
Meeting Venue
Manchester
Evaluation & Feedback
EHDN 2004
Comunicação
Folha de Contacto
Sala de conversação
Lista de correio - público
Newsletter
Ofertas de trabalho
data
descrição
tamanho
autor
documento
04.05.26
Stem cells for basic research on HD
32 kB
anonymous
ehdn-2012-ellerby
04.05.26
Stem cells for basic research on HD
32 kB
anonymous
ehdn-2012-l-thompson-empty-file
04.05.26
Keynote presentations
32 kB
anonymous
ehdn-2012-aronin-empty-file
04.05.26
Post-translational modifications of huntingtin
32 kB
anonymous
ehdn-2012-saudou-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-quarrell-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-craufurd-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-reilmann-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-j-thompson-empty-file
04.05.26
Updates on lowering huntingtin (htt) levels
32 kB
anonymous
ehdn-2012-davidson-empty-file
04.05.26
HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplasmic aggregation and rescues synaptic dysfunction in HD mouse models
32 kB
anonymous
ehdn-2012-bates-empty-file
04.05.26
Sirt1-inhibition: SienaBiotech
32 kB
anonymous
ehdn-2012-caricasole-empty-file
04.05.26
PDE-10-inhibition: Pfizer
32 kB
anonymous
ehdn-2012-schmidt-empty-file
04.05.26
PDE-4-inhibition: GSK
32 kB
anonymous
ehdn-2012-gray-empty-file
04.05.26
Htt lowering: Medtronic-Alnylam/Isis/CHDI
32 kB
anonymous
ehdn-2012-mcdonald-empty-file
04.05.26
Phenotyping neural networks in an ovine model of HD
32 kB
anonymous
ehdn-2012-perentos-empty-file
04.05.26
Aging pathway and poly-Q neurotoxicity
32 kB
anonymous
ehdn-2012-nollen
04.05.26
NeuroNet and its potential for the study of neurodegeneration
32 kB
anonymous
ehdn-2012-wanker-empty-file
04.05.26
Behavioral assessment and management of behavioral issues
32 kB
anonymous
ehdn-2012-anderson-empty-file
04.05.26
Differential diagnosis of chorea
32 kB
anonymous
ehdn-2012-walker-empty-file
04.05.26
Post-translational modifications and proteolysis of huntingtin
32 kB
anonymous
ehdn-2012-truant-empty-file
04.05.26
Advanced HD Working Group
32 kB
anonymous
ehdn-2012-youssov-empty-file
04.05.26
Animal studies on the effects of physiotherapy
32 kB
anonymous
ehdn-2012-brooks-empty-file
04.05.26
RNA toxicity in poly-Q disorders
32 kB
anonymous
ehdn-2012-krzyzosiak
04.05.26
Longevity pathways and their relevance to human disease
32 kB
anonymous
ehdn-2012--aguilaniu-empty-file
04.05.26
Frequency of Huntington Disease - Greater than you think
32 kB
anonymous
ehdn-2012-hayden-empty-file
04.05.26
What are we really looking for in an HD drug?
32 kB
anonymous
ehdn-2012-sampaio-empty-file
04.05.26
Care, coping and research in HD – the earlier the better!
32 kB
anonymous
ehdn-2012-duerr-empty-file
04.05.26
Human physiotherapy studies
32 kB
anonymous
ehdn-2012-busse-empty-file
04.05.26
Default-mode network changes in preclinical Huntington´s disease
32 kB
anonymous
ehdn-2012-orth-empty-file
04.05.26
Cognitive alterations in HD
32 kB
anonymous
ehdn-2012-stout-empty-file
04.05.26
Lessons of the day
32 kB
anonymous
ehdn-2012-wild-empty-file
04.05.26
Clinical management of Huntington’s disease
32 kB
anonymous
ehdn-2012-nance-empty-file
04.05.26
Update on stem cell research: clinical potentials
32 kB
anonymous
ehdn-2012-brundin-empty-file
04.05.26
Critical consideration of the criteria for the motor diagnosis of HD
32 kB
anonymous
ehdn-2012-paulsen-empty-file
04.05.26
Longitudinal functional and connectivity changes during working memory performance in HD
32 kB
anonymous
ehdn-2012-georgiou-karistianis-empty-f...
04.05.26
Better global and cognitive functioning for choreatic compared to hypokinetic- rigid HD
32 kB
anonymous
ehdn-2012-t-hart-empty-file
04.05.26
Bupropion: ACTION-HD
32 kB
anonymous
ehdn-2012-priller-empty-file
04.05.26
Overview of CHDI drug development programs
32 kB
anonymous
ehdn-2012-pacifici
04.05.26
Drug discovery and development process
32 kB
anonymous
ehdn-2012-kwak-empty-file
04.05.26
Lessons of the day
32 kB
anonymous
ehdn-2012-wild-empty-file
04.05.26
Standards of Care
32 kB
anonymous
ehdn-2012-rea-empty-file
04.05.26
EHDN Update - EC elections, SBAC elections, Structure of EHDN
32 kB
anonymous
ehdn-2012-landwehrmeyer-empty-file
04.05.26
Dopaminergic stabilization in HD: pridopidine
32 kB
anonymous
ehdn-2012-kieburtz-empty-file
04.05.26
Reach2HD PBT2
32 kB
anonymous
ehdn-2012-stout-empty-file
04.05.26
PREQUEL EHDN
32 kB
anonymous
ehdn-2012-ross-empty-file
04.05.26
Juvenile Huntington's disease
32 kB
anonymous
a03-juvenile-hd
04.05.26
Default-mode network changes in preclinical Huntington’s disease
32 kB
anonymous
a04-default-mode-network-changes
04.05.26
New assessment tools (cognitive batteries)
32 kB
anonymous
ehdn-2012-stout-empty-file
04.05.26
Poster Awards
32 kB
anonymous
ehdn-2012-landwehrmeyer-empty-file
04.05.26
REGISTRY and Enroll-HD
32 kB
anonymous
ehdn-2012-landwehrmeyer-empty-file
04.05.26
Better global and cognitive functioning for choreatic compared to hypokinetic-rigid Huntington’s disease
32 kB
anonymous
a06-better-global-and-cognitive-functi...
04.05.26
Progress in HD research and HD advocacy: a personal view
32 kB
anonymous
ehdn-2012-sabine-empty-file
04.05.26
Juvenile HD Working Group
32 kB
anonymous
ehdn-2012-quarrell
04.05.26
MRI as a potential marker for HD
32 kB
anonymous
ehdn-2012-scahill
04.05.26
Defining predictors of disease
32 kB
anonymous
a11-induced-pluripotent-stem-cells
04.05.26
Presentation of the HDYO website
32 kB
anonymous
ehdn-2012-ellison
04.05.26
Huntingtin
32 kB
anonymous
ehdn-2012-cattaneo
04.05.26
Falling in love, staying in love
32 kB
anonymous
eha-2012-mol
04.05.26
Defining predictors of disease
32 kB
anonymous
ehdn-2012-tabrizi
04.05.26
Critical consideration of the criteria for the motor diagnosis of Huntington disease
32 kB
anonymous
a07-critical-consideration-criteria-mo...
04.05.26
New assessment tools (cognitive batteries)
32 kB
anonymous
ehdn-2012-bachoud-levi-empty-file
04.05.26
Brain imaging as a potential marker for HD (PET)
32 kB
anonymous
ehdn-2012-varrone-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-reilmann-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-craufurd-empty-file
04.05.26
Scientific strategy of EHDN
32 kB
anonymous
ehdn-2012-bronzova
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-quarrell-empty-file
04.05.26
Training on HD assessments including HD-CC
32 kB
anonymous
ehdn-2012-thompson-empty-file
04.05.26
Common issues/problems/inconsistencies in HD assessments
32 kB
anonymous
ehdn-2012-ferreira-empty-file
04.05.26
HD for Basic Scientists
32 kB
anonymous
ehdn-2012-landwehrmeyer-empty-file
11.04.13
Plenary Session I: ‘A look ahead’
33
blankin
Plenary-Session-I
11.04.13
Plenary Session II: ‘Frontiers in biology and their relevance to Huntington’s disease’
33
blankin
Plenary-Session-II
11.04.13
Plenary Session III: ‘Science practice at EHDN’
33
blankin
Plenary-Session-III
11.04.13
Short Communications I: 'Scientific Presentations: 10’ and 5’ questions – selected from submissions'
33
blankin
Short-Communications-I
11.04.13
Plenary Session IV: Keynote presentations
33
blankin
Plenary-Session-IV
11.04.13
Roundup I
33
blankin
Roundup-I
11.04.13
Breakfast teaching courses Sat
33
blankin
Breakfast-teaching-courses-sat
11.04.13
Plenary Session V: ‘Understanding and manipulating the pathogenic process in Huntington’s disease’
33
blankin
Plenary-Session-V
11.04.13
Plenary Session VI: Keynote presentations
33
blankin
Plenary-Session-VI
11.04.13
Short communications II: Scientific presentations
33
blankin
Short-communications-II
11.04.13
Plenary Session VII: ‘Therapeutic development programs in Huntington’s Disease’
33
blankin
Plenary-Session-VII
08.04.13
Plenary Session VIII: EHDN Business Meeting
33
blankin
Plenary-Session-VIII
08.04.13
Roundup II
33
blankin
Roundup-II
08.04.13
Breakfast teaching courses Sun
33
blankin
Breakfast-teaching-courses-sun
08.04.13
Plenary Session IX: ‘Tools and outcome to monitor disease progression and response to therapy’
33
blankin
Plenary-Session-IX
08.04.13
Roundup III
33
blankin
Roundup-III
08.04.13
EHA meeting
33
blankin
EHA-meeting
08.04.13
Oral Presentations
33
blankin
Oral-Presentations
Pasta contém 87 documentos.
about us
|
privacy statement
|
disclaimer
|
terms of use